Serum Institute of India to acquire stake in IntegriMedical

2024-05-20

疫苗并购

Serum Institute of India to acquire stake in IntegriMedical

Preview

来源: Pharmaceutical Technology

SII will acquire a 20% stake in IntegriMedical to advance the technology. Credit: T. Schneider / Shutterstock.com.

Vaccine manufacturer the Serum Institute of India (SII) has announced plans to make a strategic investment in IntegriMedical, acquiring a stake of 20%, to progress the development of needle-free injection system (N-FIS) technology.

The investment aligns with SII’s strategy to enhance patient compliance, lower needle-stick injuries and improve the efficacy of liquid medications.

N-FIS technology employs a mechanically powered high-velocity jet stream to administer drugs and biologics.

The system is designed to offer a pain-free experience to patients, particularly those with needle phobia, making the process of medication administration more pleasant and stress-free.

N-FIS has secured regulatory approvals in India, Europe and the US. It holds International Organisation for Standardisation 13485 certification and a US patent.

See Also:Glenmark to market BeiGene’s oncology medicines in India

Preview

来源: Pharmaceutical Technology

GSK to divest remaining 4.2% stake in Haleon

Preview

来源: Pharmaceutical Technology

Clinical trials have demonstrated the technology’s ability to reduce pain and address needle-phobia.

The collaboration will combine SII’s vaccine production and global supply expertise with IntegriMedical’s research capabilities and drug delivery technology.

The N-FIS is set to be introduced to the Indian private market, providing an innovative alternative to conventional needle-based injections.

The technology’s benefits include the elimination of needle phobia, pain reduction during drug administration, ease of use and the prevention of cross-contamination.

Serum Institute of India CEO Adar Poonawalla said: “At SII, we are constantly seeking opportunities to invest in technologies that align with our mission to make healthcare accessible and affordable for people worldwide.

“IntegriMedical’s needle-free injection systems (N-FIS) represent a significant advancement in drug delivery and we envision a needle-free solution to deliver vaccines. We believe this could potentially revolutionise the way we administer vaccines, making the process more comfortable for patients and healthcare professionals.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构